Triamterene
- CAS No.
- 396-01-0
- Chemical Name:
- Triamterene
- Synonyms
- triamteren;ADEMINE;dyrenium;Ademine(Triamterene);ditak;diren;dytac;dyren;teriam;diurene
- CBNumber:
- CB0663775
- Molecular Formula:
- C12H11N7
- Molecular Weight:
- 253.26
- MOL File:
- 396-01-0.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/2 8:54:58
| Melting point | 316°C |
|---|---|
| Boiling point | 386.46°C (rough estimate) |
| Density | 1.3215 (rough estimate) |
| refractive index | 1.8260 (estimate) |
| Flash point | 11 °C |
| storage temp. | 2-8°C |
| solubility | formic acid: soluble200 mg + 4 mL warm Formic Acid, clear, yellow-green |
| pka | 6.2(at 25℃) |
| form | Solid |
| color | Pale Yellow to Yellow |
| Water Solubility | <0.1 G/100 ML AT 20 ºC |
| Merck | 14,9599 |
| BRN | 266723 |
| InChIKey | FNYLWPVRPXGIIP-UHFFFAOYSA-N |
| CAS DataBase Reference | 396-01-0(CAS DataBase Reference) |
| NIST Chemistry Reference | Triamterene(396-01-0) |
| IARC | 2B (Vol. 108) 2016 |
| EPA Substance Registry System | Triamterene (396-01-0) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P270-P301+P312-P302+P352-P305+P351+P338 | |||||||||
| Hazard Codes | Xn,T,F | |||||||||
| Risk Statements | 22-36/37/38-36/38-23/25-39/23/24/25-23/24/25-11 | |||||||||
| Safety Statements | 26-36/37/39-45-33-24-16-7-36/37 | |||||||||
| RIDADR | 2811 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | UO3470000 | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 2933997500 | |||||||||
| NFPA 704 |
|
Triamterene price More Price(6)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | T4143 | Triamterene ≥99% | 396-01-0 | 10G | ₹8447.1 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | T4143 | Triamterene ≥99% | 396-01-0 | 25G | ₹15773.1 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1722 | Triamterene Pharmaceutical Secondary Standard; Certified Reference Material | 396-01-0 | 400MG | ₹15057.58 | 2022-06-14 | Buy |
| ALFA India | ALF-B20044-22 | 2,4,7-Triamino-6-phenylpteridine, 98% | 396-01-0 | 100g | ₹59477 | 2022-05-26 | Buy |
| ALFA India | ALF-B20044-14 | 2,4,7-Triamino-6-phenylpteridine, 98% | 396-01-0 | 25g | ₹14869 | 2022-05-26 | Buy |
Triamterene Chemical Properties,Uses,Production
Description
Triamterene is an inhibitor of the epithelial sodium channel (ENaC; IC50 = 4.5 μM for the rat channel). In vivo, triamterene (0.5-32 mg/animal) enhances sodium secretion and decreases potassium secretion in adrenalectomized rats. Formulations containing triamterene have been used in the treatment of edema. This product is also available as an analytical reference standard .
Chemical Properties
Yellow Solid
Uses
Triamterene is a potassium-sparing diuretic ie, it inhibits the urinary excretion of potassium
Biological Functions
Triamterene (Dyrenium) results in changes in urinary electrolyte patterns that are qualitatively similar to those produced by spironolactone. The mechanism by which this agents bring about the alterations in electrolyte loss, however, is quite different. Triamterene produces this effects whether or not aldosterone or any other mineralocorticoid is present. The action of this drug is clearly unrelated to endogenous mineralocorticoid activity, and this drug is effective in adrenalectomized patients.
General Description
Odorless yellow powder or crystalline solid. Melting point 316°C. Almost tasteless at first and with a slightly bitter aftertaste. Acidified solutions give a blue fluorescence. Used as a diuretic drug.
Air & Water Reactions
Sensitive to light; slowly oxidized upon exposure to air. Insoluble in water.
Reactivity Profile
2,4,7-Triamino-6-phenylpteridine neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen may be generated in combination with strong reducing agents, such as hydrides.
Fire Hazard
Flash point data for 2,4,7-Triamino-6-phenylpteridine are not available; however, 2,4,7-Triamino-6-phenylpteridine is probably combustible.
Mechanism of action
Triamterene is a pyrazine derivative that inhibits reabsorption of sodium ions without
increasing excretion of potassium ions. It exhibits the same approximate effect as spironolactone;
however, it does not competitively bind with aldosterone receptors. Its action does
not have an effect on secretion of aldosterone or its antagonists, which are a result of direct
action on renal tubules.
This potassium sparing diuretic causes a moderate increase in excretion of sodium and
bicarbonate ions in urine, and it raises excretion of potassium and ammonia ions. It has little
effect on urine volume.
Clinical Use
Triamterene can be used in the treatment of congestive
heart failure, cirrhosis, and the edema caused by
secondary hyperaldosteronism. It is frequently used in
combination with other diuretics except spironolactone.
Amiloride, but not triamterene, possesses antihypertensive
effects that can add to those of the thiazides.
These K+-sparing diuretics have low efficacy when
used alone, since only a small amount of total Na reabsorption
occurs at more distal sites of the nephron.
These compounds are used primarily in combination
with other diuretics, such as the thiazides and loop diuretics,
to prevent or correct hypokalemia. The availability
of fixed-dose mixtures of thiazides with nonsteroidal
K+-sparing compounds has proved a rational
form of drug therapy. Both triamterene and amiloride
are available alone or in combination with hydrochlorothiazide.
Side effects
Because the actions of triamterene and amiloride are independent of plasma aldosterone levels, their prolonged administration is likely to result in hyperkalemia. Both amiloride and triamterene are contraindicated in patients with hyperkalemia.Triamterene should not be given to patients with impaired renal function. Potassium intake must be reduced, especially in outpatients.A folic acid deficiency has been reported to occur occasionally following the use of triamterene.
Triamterene Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Rivashaa Agrotech Biopharma Pvt. Ltd. | +91-26463395 +91-7926462688 | Gujarat, India | 1615 | 58 | Inquiry |
| Bal Pharma Limited | +91-8041379581 +91-8041379500 | Karnataka, India | 20 | 58 | Inquiry |
| CHEMSWORTH | +91-261-2397244 | New Delhi, India | 6707 | 30 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Shaivya Pharmachem. | 08048371708Ext 729 | Gujarat, India | 56 | 58 | Inquiry |
| Alfa Aesar | 1 800 209 7001 | Maharashtra, India | 6913 | 58 | Inquiry |
| Ipca Laboratories Ltd. | 91-22-62105845 | Maharashtra, India | 75 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
396-01-0(Triamterene)Related Search:
1of4
chevron_right